Skin & Pigmentation

Melanotan I

A melanocortin agonist; the approved form treats a rare light-sensitivity disorder.

What is Melanotan I?

Melanotan I is a melanocortin agonist that stimulates melanin production. Its clinically developed form, afamelanotide (Scenesse), is approved to reduce phototoxicity in people with erythropoietic protoporphyria (EPP).

Also known as: MT-1, Afamelanotide, Scenesse

Read the in-depth Melanotan I guide

How Melanotan I is studied

Melanotan I is a melanocortin agonist that stimulates melanin production. Its clinically developed form, afamelanotide (Scenesse), is approved to reduce phototoxic reactions in people with erythropoietic protoporphyria (EPP) by increasing protective pigmentation.

Commonly researched for

Skin pigmentationPhotoprotectionEPP (approved use)

Research status

Approved (as afamelanotide) for a specific rare condition.

Important considerations

The approved form is prescription-only for EPP. Unregulated tanning use is not medically endorsed.

View published research on PubMed

Melanotan I — frequently asked questions

As afamelanotide (Scenesse), it is approved to reduce phototoxicity in people with erythropoietic protoporphyria (EPP).

No. Melanotan I has an approved clinical form for a specific condition; Melanotan II is broader-acting and not approved.

The approved form is prescription-only for EPP. Unregulated cosmetic use is not medically endorsed.

This page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.